Targeting people with type 2 diabetes can cost-effectively identify missed heart failure
What is the aim?
A series of studies have aimed to evaluate several screening strategies and their cost-effectiveness to assess the risk of heart failure in people with type 2 diabetes.1 They included five strategies using a combination of tools, such as electronic health records, symptoms, natriuretic peptide testing and echocardiography.
What has been achieved?
The studies showed that screening for heart failure with preserved ejection fraction (HFpEF) in people with type 2 diabetes aged 60 or over increased life expectancy in a cost-effective way.1 2 The most cost-effective strategy calculated heart failure risk according to electronic health records and assessment of symptoms.1 Those with a heart failure risk of over 20% had an echocardiogram to confirm heart failure diagnosis. These findings have led to clinician-led calls for heart failure screening among people with type 2 diabetes.3
- van Giessen A, Boonman-de Winter LJ, Rutten FH, et al. 2016. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol 15: 48
- Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. 2015. Efficiently screening heart failure in patients with type 2 diabetes. Eur J Heart Fail 17(2): 187-95
- Boonman-de Winter LJ, Cramer MJ, Hoes AW, et al. 2016. Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change. Neth Heart J 24(4): 237-43